FIELD: medicine.
SUBSTANCE: drug preparation represents a composition containing: lappaconitine hydrobromide 0.02 - 0.06 g, pregelatinised starch 0.0335 - 0.0536 g, lactose monohydrate 0.058 - 0.122 g, hypromellose 0.078 - 0.161 g, calcium stearate 0.002 - 0.004 g and colloidal silicone dioxide 0.002 - 0.004 g.
EFFECT: prolonged antiarrhythmic action of the active ingredient lappaconitine hydrobromide with accessory alkaloids.
5 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIARRHYTHMIC DRUG | 2017 |
|
RU2664668C1 |
| MEANS WITH ANTIARRHYTHMIC ACTION | 2016 |
|
RU2630967C1 |
| THERAPEUTIC AGENT FOR TREATMENT OF DIFFERENT FORMS OF HEART RHYTHM DISTURBANCES | 2000 |
|
RU2180583C1 |
| 5'-BROMOLAPPACONITINE HYDROBROMIDE POSSESSING ANTI-ARRHYTHMIC ACTIVITY | 2005 |
|
RU2295524C1 |
| PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING AND USING DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION CONTAINING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2021 |
|
RU2818092C1 |
| METHOD FOR PREVENTION OF CARDIAC RHYTHM DISTURBANCE IN CORONARY BYPASS | 2009 |
|
RU2392939C1 |
| ANTIARRHYTHMIC AGENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION BASED ON ANTIARRHYTHMIC AGENT | 2022 |
|
RU2825632C2 |
| SOLID PHARMACEUTICAL FORM OF IMMEDIATELY RELEASING ZAFIRLUKAST AND METHOD OF ITS PRODUCTION | 2016 |
|
RU2619213C1 |
| PHARMACEUTICAL COMPOSITION WITH ANTIARRHYTHMIC ACTIVITY OF VARIOUS ETIOLOGIES | 2021 |
|
RU2783944C1 |
| N-(BETA-HYDROXYETHYL)-CYTISINE HYDROCHLORIDE ELICITING ANTI-ARRHYTHMIC ACTIVITY | 2002 |
|
RU2228179C2 |
